Identification of signature genes and drug candidates for primary plasma cell leukemia: An integrated system biology approach

Raushan Kumar Chaudhary,Prakash Patil, L. Ananthesh,Mahendra Gowdru Srinivasa,Uday Venkat Mateti,Vijith Shetty,Pukar Khanal

Computers in Biology and Medicine（2023）

引用 2|浏览2

暂无评分

摘要

•Plasma cell leukemia is distinguished by the excessive proliferation of plasma cells in the peripheral blood and bone marrow.•TP53, MAPK1, SOCS1, MBD3, and YES1 are expressed in patients with newly diagnosed plasma cell leukemia.•Oxaliplatin, mitoxantrone, and ponatinib possess binding affinity towards TP53, MAKP1, and YES1 providing a strategy to treat plasma cell leukemia.

查看译文

关键词

primary plasma cell leukemia,cell leukemia,signature genes,integrated system biology approach

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要